Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.58 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.40 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | MAX | P61244 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28087917 | 0.89 | PTPN1 (0.44) | FOLH1PTPN1PTPN2PTPN6TMEM97 | |
| SCHEMBL22227471 | 0.84 | LTB4R2 (0.49) | LTB4R2 | |
| SCHEMBL6677061 | 0.77 | FOLH1 (0.61) | FOLH1LTB4RLTB4R2PTPN1PTPN2 | |
| SCHEMBL22227469 | 0.77 | FOLH1 (0.45) | FOLH1EIF4ESMN1; SMN2 | |
| SCHEMBL9407400 | 0.77 | FOLH1 (0.75) | FOLH1LTB4RLTB4R2PTPN1PTPN2 | |
| SCHEMBL3639419 | 0.77 | HNF4A (0.45) | FOLH1PTPN1PTPN2PTPN6HSD17B10 | |
| SCHEMBL2998914 | 0.76 | HNF4A (0.52) | PTPN1PTPN2PTPN6TMEM97 | |
| SCHEMBL2713834 | 0.76 | HNF4A (0.52) | PTPN1PTPN2PTPN6TMEM97 | |
| SCHEMBL28087997 | 0.76 | HDAC7 (0.43) | FOLH1LTB4RLTB4R2PTPN1PTPN2 | |
| SCHEMBL28088001 | 0.75 | IDO1 (0.52) | TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622612-B2 | Tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2009-11-24 | — | — | US | claimed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | claimed |
| US-7622612-B2 | Tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2009-11-24 | — | — | US | disclosed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021427-A1 | Novel tricyclic derivatives and their use | NFATC1, IL2, CCL2 | FOLH1 131/4885LTB4R 748/4885LTB4R2 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.